{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:14Z","timestamp":1792790474481,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000005"],"award-info":[{"award-number":["UL1TR000005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The family of juvenile xanthogranuloma family neoplasms (JXG) with ERK-pathway mutations are now classified within the \u201cL\u201d (Langerhans) group, which includes Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD). Although the\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E mutation constitutes the majority of molecular alterations in ECD and LCH, only three reported JXG neoplasms, all in male pediatric patients with localized central nervous system (CNS) involvement, are known to harbor the\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutation. This retrospective case series seeks to redefine the clinicopathologic spectrum of pediatric CNS-JXG family neoplasms in the post-BRAF era, with a revised diagnostic algorithm to include pediatric ECD. Twenty-two CNS-JXG family lesions were retrieved from consult files with 64% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200914) having informative\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E mutational testing (molecular and\/or VE1 immunohistochemistry). Of these, 71% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200910) were pediatric cases (\u226418\u2009years) and half (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u20095) harbored the\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E mutation. As compared to the\n                    <jats:italic>BRAF<\/jats:italic>\n                    wild-type cohort (WT), the\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E cohort had a similar mean age at diagnosis [\n                    <jats:italic>BRAF<\/jats:italic>\n                    \u00a0V600E: 7\u2009years (3\u201312 y), vs. WT: 7.6\u2009years (1\u201318 y)] but demonstrated a stronger male\/female ratio (\n                    <jats:italic>BRAF\u00a0<\/jats:italic>\n                    V600E: 4 vs WT: 0.67), and had both more multifocal CNS disease (\u00a0\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E: 80% vs WT: 20%) and systemic disease (\n                    <jats:italic>BRAF<\/jats:italic>\n                    \u00a0V600E: 40% vs WT: none). Radiographic features of CNS-JXG varied but typically included enhancing CNS mass lesion(s) with associated white matter changes in a subset of\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E neoplasms. After clinical-radiographic correlation, pediatric ECD was diagnosed in the\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E cohort. Treatment options varied, including surgical resection, chemotherapy, and targeted therapy with BRAF-inhibitor dabrafenib in one mutated case.\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E CNS-JXG neoplasms appear associated with male gender and aggressive disease presentation including pediatric ECD. We propose a revised diagnostic algorithm for CNS-JXG that includes an initial morphologic diagnosis with a final integrated diagnosis after clinical-radiographic and molecular correlation, in order to identify cases of pediatric ECD. Future studies with long-term follow-up are required to determine if pediatric\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E positive CNS-JXG neoplasms are a distinct entity in the L-group histiocytosis category or represent an expanded pediatric spectrum of ECD.\n                  <\/jats:p>","DOI":"10.1186\/s40478-019-0811-6","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T07:03:24Z","timestamp":1572851004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-6422","authenticated-orcid":false,"given":"J.","family":"Picarsic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pysher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fluchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Surrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fellig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Mobley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Sharples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shekdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","volume":"131","author":"O Abla","year":"2018","unstructured":"Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J et al (2018) Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131:2877\u20132890. https:\/\/doi.org\/10.1182\/blood-2018-03-839753","journal-title":"Blood"},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, Perez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F et al (2011) CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 117:2778\u20132782. https:\/\/doi.org\/10.1182\/blood-2010-06-294108","journal-title":"Blood"},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919\u20131923. https:\/\/doi.org\/10.1182\/blood-2010-04-279083","journal-title":"Blood"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bjd.17420","volume":"180","author":"F Bellinato","year":"2019","unstructured":"Bellinato F, Maurelli M, Colato C, Balter R, Girolomoni G, Schena D (2019) BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. Br J Dermatol 180:933\u2013934. https:\/\/doi.org\/10.1111\/bjd.17420","journal-title":"Br J Dermatol"},{"key":"811_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ et al (2014) BRAF V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211:669\u2013683. https:\/\/doi.org\/10.1084\/jem.20130977","journal-title":"J Exp Med"},{"key":"811_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3171\/jns.2000.93.2.0335","volume":"93","author":"J Bostrom","year":"2000","unstructured":"Bostrom J, Janssen G, Messing-Junger M, Felsberg JU, Neuen-Jacob E, Engelbrecht V, Lenard HG, Bock WJ, Reifenberger G (2000) Multiple intracranial juvenile xanthogranulomas. Case report J Neurosurg 93:335\u2013341. https:\/\/doi.org\/10.3171\/jns.2000.93.2.0335","journal-title":"Case report J Neurosurg"},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1525-1470.1993.tb00018.x","volume":"10","author":"R Botella-Estrada","year":"1993","unstructured":"Botella-Estrada R, Sanmartin O, Grau M, Alegre V, Mas C, Aliaga A (1993) Juvenile xanthogranuloma with central nervous system involvement. Pediatr Dermatol 10:64\u201368","journal-title":"Pediatr Dermatol"},{"key":"811_CR8","first-page":"201","volume":"58","author":"WH Burgdorf","year":"1996","unstructured":"Burgdorf WH, Zelger B (1996) The non-Langerhans' cell histiocytoses in childhood. Cutis 58:201\u2013207","journal-title":"Cutis"},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2350\/09-03-0622-oa.1","volume":"13","author":"EC Castro","year":"2010","unstructured":"Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, Graf N, Levy N, Lowe EJ, Manning JT Jr et al (2010) Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol 13:225\u2013237. https:\/\/doi.org\/10.2350\/09-03-0622-oa.1","journal-title":"Pediatr Dev Pathol"},{"key":"811_CR10","doi-asserted-by":"publisher","unstructured":"Chakraborty R, Hampton OA, Abhyankar H, Zinn DJ, Grimes A, Skull B, Eckstein O, Mahmood N, Wheeler DA, Lopez-Terrada D et al (2017) Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.17521","DOI":"10.18632\/oncotarget.17521"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"46065","DOI":"10.18632\/oncotarget.17521","volume":"8","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Hampton OA, Abhyankar H, Zinn DJ, Grimes A, Skull B, Eckstein O, Mahmood N, Wheeler DA, Lopez-Terrada D et al (2017) Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget 8:46065\u201346070. https:\/\/doi.org\/10.18632\/oncotarget.17521","journal-title":"Oncotarget"},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41379-018-0168-6","volume":"32","author":"KTE Chang","year":"2019","unstructured":"Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N, Campbell J, Mechinaud F, Campbell M, Super L et al (2019) ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 32:598\u2013608. https:\/\/doi.org\/10.1038\/s41379-018-0168-6","journal-title":"Mod Pathol"},{"key":"811_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","volume":"27","author":"LP Dehner","year":"2003","unstructured":"Dehner LP (2003) Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 27:579\u2013593","journal-title":"Am J Surg Pathol"},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2016-06-725143","volume":"128","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Brody L, Arcila M, Bowers C, Fluchel M (2016) Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood 128:1896\u20131898. https:\/\/doi.org\/10.1182\/blood-2016-06-725143","journal-title":"Blood"},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124:483\u2013492. https:\/\/doi.org\/10.1182\/blood-2014-03-561381","journal-title":"Blood"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2159-8290.cd-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F et al (2016) Diverse and targetable kinase alterations drive Histiocytic neoplasms. Cancer discovery 6:154\u2013165. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0913","journal-title":"Cancer discovery"},{"key":"811_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH et al (2019) Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 567:521\u2013524. https:\/\/doi.org\/10.1038\/s41586-019-1012-y","journal-title":"Nature"},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-016-0490-3","volume":"11","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, Holodny AI, Raj A (2016) Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet J Rare Dis 11:109\u2013109. https:\/\/doi.org\/10.1186\/s13023-016-0490-3","journal-title":"Orphanet J Rare Dis"},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J et al (2018) Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell Histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384\u2013388. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5029","journal-title":"JAMA Oncol"},{"issue":"15","key":"811_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","volume":"133","author":"Olive S. Eckstein","year":"2019","unstructured":"Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE (2019) Clinical responses and persistent BRAFV600E + blood cells in children with LCH treated with MAPK pathway inhibition. Blood. https:\/\/doi.org\/10.1182\/blood-2018-10-878363","journal-title":"Blood"},{"key":"811_CR21","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672\u20132681. https:\/\/doi.org\/10.1182\/blood-2016-01-690636","journal-title":"Blood"},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00234-002-0819-6","volume":"44","author":"U Ernemann","year":"2002","unstructured":"Ernemann U, Skalej M, Hermisson M, Platten M, Jaffe R, Voigt K (2002) Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. Neuroradiology 44:759\u2013763. https:\/\/doi.org\/10.1007\/s00234-002-0819-6","journal-title":"Neuroradiology"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras JI, O'Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, Malayeri AA, Chen MY, Gardner PJ, Alvarado-Enriquez JR et al (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1:357\u2013366. https:\/\/doi.org\/10.1182\/bloodadvances.2016001784","journal-title":"Blood Adv"},{"key":"811_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000078","volume":"2","author":"P Euskirchen","year":"2015","unstructured":"Euskirchen P, Haroche J, Emile JF, Buchert R, Vandersee S, Meisel A (2015) Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm 2:e78. https:\/\/doi.org\/10.1212\/nxi.0000000000000078","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.3324\/haematol.2018.190934","volume":"103","author":"G Fatobene","year":"2018","unstructured":"Fatobene G, Haroche J, Helias-Rodzwicz Z, Charlotte F, Taly V, Ferreira AM, Abdo ANR, Rocha V, Emile JF (2018) BRAF V600E mutation detected in a case of Rosai-Dorfman disease. Haematologica 103:e377\u2013e379. https:\/\/doi.org\/10.3324\/haematol.2018.190934","journal-title":"Haematologica"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0190-9622(86)70049-2","volume":"14","author":"DB Flach","year":"1986","unstructured":"Flach DB, Winkelmann RK (1986) Juvenile xanthogranuloma with central nervous system lesions. J Am Acad Dermatol 14:405\u2013411","journal-title":"J Am Acad Dermatol"},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000180303","volume":"44","author":"DH Fulkerson","year":"2008","unstructured":"Fulkerson DH, Luerssen TG, Hattab EM, Kim DL, Smith JL (2008) Long-term follow-up of solitary intracerebral juvenile xanthogranuloma. Case report and review of the literature. Pediatr Neurosurg 44:480\u2013485. https:\/\/doi.org\/10.1159\/000180303","journal-title":"Pediatr Neurosurg"},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","volume":"30","author":"S Garces","year":"2017","unstructured":"Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, Garces JC, Khoury JD, Yin CC (2017) Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 30:1367\u20131377. https:\/\/doi.org\/10.1038\/modpathol.2017.55","journal-title":"Mod Pathol"},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/brain\/awh403","volume":"128","author":"N Grois","year":"2005","unstructured":"Grois N, Prayer D, Prosch H, Lassmann H (2005) Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 128:829\u2013838. https:\/\/doi.org\/10.1093\/brain\/awh403","journal-title":"Brain"},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700\u20132703. https:\/\/doi.org\/10.1182\/blood-2012-05-430140","journal-title":"Blood"},{"key":"811_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche J, Cohen-Aubart F, Emile J-F, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495\u20131500. https:\/\/doi.org\/10.1182\/blood-2012-07-446286","journal-title":"Blood"},{"key":"811_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1200\/jco.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, Barete S, Charlotte F, Cluzel P, Donadieu J et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol 33:411\u2013418. https:\/\/doi.org\/10.1200\/jco.2014.57.1950","journal-title":"J Clin Oncol"},{"key":"811_CR33","unstructured":"Haynes ESE, Guo H, Jaffe R, and Picarsic J. (2017) S100 Immunohistochemistry In 65 Localized Juvenile Xanthogranuloma Family Lesions: Understanding Staining Patterns With Clinicopathologic Correlation. Spring 2017 Meeting of the Society for Pediatric Pathology. Pediatric and Developmental Pathology, City, pp 526\u2013562, A543"},{"issue":"7","key":"811_CR34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"Baptiste Hervier","year":"2014","unstructured":"Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A, Lifermann F, Villabona C, Graffin B, Hermine O et al (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation: a multicenter study of 23 cases. Blood. https:\/\/doi.org\/10.1182\/blood-2013-12-543793","journal-title":"Blood"},{"key":"811_CR35","doi-asserted-by":"crossref","unstructured":"Holck S, Nielsen HJ, Pedersen N, Larsson LI (2015) Phospho-ERK1\/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma. Oncotarget 6:34321-34328","DOI":"10.18632\/oncotarget.5761"},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.pas.0000147395.01229.06","volume":"29","author":"D Janssen","year":"2005","unstructured":"Janssen D, Harms D (2005) Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the Kiel pediatric tumor registry. Am J Surg Pathol 29:21\u201328","journal-title":"Am J Surg Pathol"},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.phoj.2017.09.004","volume":"2","author":"MR Khan","year":"2017","unstructured":"Khan MR, Ashraf MS, Belgaumi AF (2017) Erdheim Chester disease\u2013an unusual presentation of a rare histiocytic disease in a 3-year old boy. Pediatr Hematol Oncol J 2:59\u201362. https:\/\/doi.org\/10.1016\/j.phoj.2017.09.004","journal-title":"Pediatr Hematol Oncol J"},{"key":"811_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00381-015-2929-6","volume":"32","author":"S Kim","year":"2016","unstructured":"Kim S, Lee M, Shin HJ, Lee J, Suh YL (2016) Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report. Childs Nerv Syst 32:893\u2013896. https:\/\/doi.org\/10.1007\/s00381-015-2929-6","journal-title":"Childs Nerv Syst"},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.braindev.2006.08.013","volume":"29","author":"S Kumandas","year":"2007","unstructured":"Kumandas S, Kurtsoy A, Canoz O, Patiroglu T, Yikilmaz A, Per H (2007) Erdheim Chester disease: cerebral involvement in childhood. Brain Dev 29:227\u2013230. https:\/\/doi.org\/10.1016\/j.braindev.2006.08.013","journal-title":"Brain Dev"},{"key":"811_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89473","volume":"2","author":"LH Lee","year":"2017","unstructured":"Lee LH, Gasilina A, Roychoudhury J, Clark J, McCormack FX, Pressey J, Grimley MS, Lorsbach R, Ali S, Bailey M et al (2017) Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight 2:e89473. https:\/\/doi.org\/10.1172\/jci.insight.89473","journal-title":"JCI Insight"},{"key":"811_CR41","doi-asserted-by":"publisher","unstructured":"Lopez Nunez O, Schmitt L, Picarsic J (2018 ) Diagnostic Value of BRAF VE1 Immunohistochemistry as a Reliable Marker of Neoplasms Harboring BRAF V600E Mutation in Pediatric and Histiocytic Neoplasms. A17. 2018 SPP fall abstracts. Pediatr Dev Pathol 0: 1093526618806423. https:\/\/doi.org\/10.1177\/1093526618806423","DOI":"10.1177\/1093526618806423"},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"811_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature23672","volume":"549","author":"E Mass","year":"2017","unstructured":"Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK et al (2017) A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549:389\u2013393. https:\/\/doi.org\/10.1038\/nature23672","journal-title":"Nature"},{"key":"811_CR44","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/bloodadvances.2019000093","volume":"3","author":"R Mastropolo","year":"2019","unstructured":"Mastropolo R, Close A, Allen SW, McClain KL, Maurer S, Picarsic J (2019) BRAF V600E mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv 3:1848\u20131853. https:\/\/doi.org\/10.1182\/bloodadvances.2019000093","journal-title":"Blood Adv"},{"key":"811_CR45","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/cncr.31348","volume":"124","author":"KL McClain","year":"2018","unstructured":"McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H, Scull B, Shih A, Lim KPH, Eckstein O et al (2018) CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607\u20132620. https:\/\/doi.org\/10.1002\/cncr.31348","journal-title":"Cancer"},{"key":"811_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajoc.2017.09.004","volume":"9","author":"P Meyer","year":"2018","unstructured":"Meyer P, Graeff E, Kohler C, Munier F, Bruder E (2018) Juvenile xanthogranuloma involving concurrent iris and skin: clinical, pathological and molecular pathological evaluations. Am J Ophthalmol Case Rep 9:10\u201313. https:\/\/doi.org\/10.1016\/j.ajoc.2017.09.004","journal-title":"Am J Ophthalmol Case Rep"},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/pbc.21252","volume":"50","author":"A Orsey","year":"2008","unstructured":"Orsey A, Paessler M, Lange BJ, Nichols KE (2008) Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 50:927\u2013930. https:\/\/doi.org\/10.1002\/pbc.21252","journal-title":"Pediatr Blood Cancer"},{"key":"811_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/jnen\/nlx095","volume":"76","author":"Z Pan","year":"2017","unstructured":"Pan Z, Kleinschmidt-DeMasters BK (2017) CNS Erdheim-Chester disease: a challenge to diagnose. J Neuropathol Exp Neurol 76:986\u2013996. https:\/\/doi.org\/10.1093\/jnen\/nlx095","journal-title":"J Neuropathol Exp Neurol"},{"key":"811_CR49","doi-asserted-by":"publisher","unstructured":"Picarsic J, Alaggio R, Jaffe R, Diamond EL, Durham B, Abdel-Wahab O (2019) Abstracts from the 34th annual meeting of the Histiocyte society Lisbon, Portugal, October 22\u201323, 2018. 66:e27548. https:\/\/doi.org\/10.1002\/pbc.27548","DOI":"10.1002\/pbc.27548"},{"key":"811_CR50","first-page":"3","volume-title":"Histiocytic Disorders","author":"Jennifer Picarsic","year":"2017","unstructured":"Picarsic J, Jaffe R (2017) Pathology of Histiocytic disorders and neoplasms and related disorders. In: Abla O. JGe (ed) Histiocytic disorders. Springer, City, pp 3\u201350"},{"key":"811_CR51","doi-asserted-by":"crossref","unstructured":"Pinney SS, Jahan-Tigh RR, Chon S (2016) Generalized eruptive histiocytosis associated with a novel fusion in LMNA-NTRK1. Dermatol Online J 22.","DOI":"10.5070\/D3228032091"},{"key":"811_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ana.25281","volume":"84","author":"TE Richardson","year":"2018","unstructured":"Richardson TE, Wachsmann M, Oliver D, Abedin Z, Ye D, Burns DK, Raisanen JM, Greenberg BM, Hatanpaa KJ (2018) BRAF mutation leading to central nervous system rosai-dorfman disease. Ann Neurol 84:147\u2013152. https:\/\/doi.org\/10.1002\/ana.25281","journal-title":"Ann Neurol"},{"key":"811_CR53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.hoc.2015.06.004","volume":"29","author":"BJ Rollins","year":"2015","unstructured":"Rollins BJ (2015) Genomic alterations in Langerhans cell Histiocytosis. Hematol Oncol Clin North Am 29:839\u2013851. https:\/\/doi.org\/10.1016\/j.hoc.2015.06.004","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"811_CR54","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/cup.13285","volume":"45","author":"Kristen N. Ruby","year":"2018","unstructured":"Ruby KN, Deng AC, Zhang J, LeBlanc RE, Linos KD, Yan S (2018) Emperipolesis and S100 expression may be seen in cutaneous xanthogranulomas: a multi-institutional observation. J Cutan Pathol. https:\/\/doi.org\/10.1111\/cup.13285","journal-title":"Journal of Cutaneous Pathology"},{"key":"811_CR55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jocn.2012.05.019","volume":"20","author":"I Tamir","year":"2013","unstructured":"Tamir I, Davir R, Fellig Y, Weintraub M, Constantini S, Spektor S (2013) Solitary juvenile xanthogranuloma mimicking intracranial tumor in children. J Clin Neurosci 20:183\u2013188. https:\/\/doi.org\/10.1016\/j.jocn.2012.05.019","journal-title":"J Clin Neurosci"},{"key":"811_CR56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.humpath.2017.04.026","volume":"69","author":"P Techavichit","year":"2017","unstructured":"Techavichit P, Sosothikul D, Chaichana T, Teerapakpinyo C, Thorner PS, Shuangshoti S (2017) BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. Hum Pathol 69:118\u2013122. https:\/\/doi.org\/10.1016\/j.humpath.2017.04.026","journal-title":"Hum Pathol"},{"key":"811_CR57","doi-asserted-by":"publisher","first-page":"100124","DOI":"10.1016\/j.xocr.2019.100124","volume":"12","author":"SM Tittman","year":"2019","unstructured":"Tittman SM, Nassiri AM, Manzoor NF, Yawn RJ, Mobley BC, Wellons JC, Rivas A (2019) Juvenile xanthogranuloma of the cerebellopontine angle: a case report and review of the literature. Otolaryngol Case Rep 12:100124. https:\/\/doi.org\/10.1016\/j.xocr.2019.100124","journal-title":"Otolaryngol Case Rep"},{"key":"811_CR58","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00701-016-2811-7","volume":"158","author":"B Wang","year":"2016","unstructured":"Wang B, Jin H, Zhao Y, Ma J (2016) The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir 158:1289\u20131297. https:\/\/doi.org\/10.1007\/s00701-016-2811-7","journal-title":"Acta Neurochir"},{"key":"811_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pbc.20246","volume":"45","author":"S Weitzman","year":"2005","unstructured":"Weitzman S, Jaffe R (2005) Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 45:256\u2013264. https:\/\/doi.org\/10.1002\/pbc.20246","journal-title":"Pediatr Blood Cancer"},{"key":"811_CR60","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/00000372-199610000-00008","volume":"18","author":"BW Zelger","year":"1996","unstructured":"Zelger BW, Sidoroff A, Orchard G, Cerio R (1996) Non-Langerhans cell histiocytoses. A new unifying concept. Am J Dermatopathol 18:490\u2013504","journal-title":"Am J Dermatopathol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-019-0811-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-019-0811-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-019-0811-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:20:40Z","timestamp":1664788840000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-019-0811-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s40478-019-0811-6","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A waiver of HIPAA Authorization and waiver of consent were approved for this study by the University of Pittsburgh Institutional Review Board (PRO12110055).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required; see above.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}